939 completed, 197 unknown, 142 recruiting, 91 terminated. 563 Not applicable, 249 Phase 3, 176 Phase 2, 165 Phase 4, 101 Phase 1.
Follow Migraine Disorders: new trials by email Literature Review of Migraine Disorders trials Research Report on Migraine Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Observational Study to Assess Migraine Prediction Tool Daily questionnaire - Migraine | Suspended | Theranica | 200 | 2030-01-01 | 2024-11-22 | |
| EMBRACE Study: Enduring Migraine Benefit From Responsive Artery Coil Embolization TEMMA Endovascular Treatment - Migraine Disorders, Refractory Migraine | Not applicable | Withdrawn | Cortex Neurovascular | 2028-03-01 | 2026-10-27 | |
| Calcitonin Gene-related Peptide Antibody in Acute Mountain Sickness Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution, Placebo - Acute Mountain Sickness | Phase 4 | Not yet recruiting | Insel Gruppe AG, University Hospital Bern | 30 | 2027-06-01 | 2026-07-01 |
| Nortriptyline Compared With Amitriptyline for Migraine Prevention at SQUH Nortriptyline, Amitriptyline - Migraine | Phase 4 | Not yet recruiting | Sultan Qaboos University | 90 | 2027-05-01 | 2026-10-02 |
| A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus) Glycerol Tributyrate - MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus) | Phase 1 / Phase 2 | Not yet recruiting | George Washington University | 24 | 2027-03-01 | 2026-10-05 |
| Migraine Menopause Study Eptinezumab 100 mg or Eptinezumab 300 mg administered intravenously in 100 mL saline solution, Placebo Normal Saline (NS) - Migraine, Menopausal | Phase 4 | Not yet recruiting | Alberta Neurologic Centre | 120 | 2027-02-01 | 2026-11-04 |
| Multimodal Therapy for Somatosensory Tinnitus Multimodal physiotherapy for TMJ and Cervical spine, Combined Exercise Program (Aerobic + Resistance + Breathing), Tinnitus-Specific Psychological Support - Ear Noise, Tinnitus, Noise Induced | Not applicable | Not yet recruiting | Charles University, Czech Republic | 160 | 2027-01-01 | 2026-03-12 |
| Effect of Atogepant on the Vestibulo-Ocular Reflex in Healthy Adults and Adults With Migraine Atogepant 60 mg, Placebo - Migraine Disorders, Brain, Healthy Adult Participants | Phase 4 | Not yet recruiting | Konrad Peter Weber | 80 | 2027-01-01 | 2026-09-17 |
| Visual Instillation of Sphenopalatine-block Intervention for ONgoing Migraine Topical solution of 4% lidocaine, Saline 0.9% - Migraine, Facial Pain or Pressure | Phase 2 | Not yet recruiting | Association of Migraine Disorders | 74 | 2027-01-01 | 2026-11-09 |
| A Pivotal Clinical Study to Evaluate the MySalvia System for the Treatment of Resistant Migraine Neurostimulator - Resistant Migraine, Chronic Migraine Headache | Not applicable | Recruiting | Salvia BioElectronics | 150 | 2026-12-01 | 2026-08-28 |
| Sequential, Multiple Assignment, Double Randomized Preference, Migraine Behavioral Trial Migraine Behavioral Treatment - Migraine, Headache | Not applicable | Not yet recruiting | Mayo Clinic | 24 | 2026-12-01 | 2026-06-16 |
| A Prospective Study of Rimegepant for Short-term Preventive Treatment of Night-shift-related Migraine in Healthcare Professionals Rimegepant 75 mg ODT, Standard Care - Migraine Disorders | Not applicable | Not yet recruiting | Chinese PLA General Hospital | 260 | 2026-12-01 | 2026-11-05 |
| Long-term Safety of BR005-036C Tablets in the Acute Treatment of Migraine in Adults BR005-036C - Migraine, With or Without Aura | Phase 3 | Not yet recruiting | Brise Pharmaceuticals Co., Ltd. | 1000 | 2026-11-20 | 2026-11-12 |
| Headache Education and Awareness vs. Daily Mindfulness Strategies - Understanding Pain BREATHE with Headache (BREATHE-HA), Enhanced Standard-of-Care: Headache Education - Migraine, Migraine in Adolescence | Not applicable | Recruiting | University of Colorado, Denver | 72 | 2026-11-10 | 2026-11-05 |
| Biological Profiles of Neuropeptides, Neurotrophins and miRNA in Migraine Rimegepant 75 MG - Migraine | Enrolling by invitation | Nordlandssykehuset HF | 60 | 2026-11-05 | 2026-11-10 | |
| Assessment of Head Awareness in Patients With Migraine in the Greek Population Migraine | Not yet recruiting | National and Kapodistrian University of Athens | 90 | 2026-11-01 | 2026-10-08 | |
| Validity and Reliability of the Greek WPAI:Migraine Migraine | Not yet recruiting | National and Kapodistrian University of Athens | 60 | 2026-11-01 | 2026-10-08 | |
| Validity and Reliability of the Greek Pain Catastrophizing Scale Migraine | Not yet recruiting | National and Kapodistrian University of Athens | 130 | 2026-11-01 | 2026-10-07 | |
| Headache and Hormone Use Among Transgender Population in Thailand: A Cross-Sectional Online Study gender-affirming hormone therapy, Gender-Affirming Surgery, HIV Pre-Exposure Prophylaxis - Headache, Migraine | Not yet recruiting | Chulalongkorn University | 500 | 2026-11-01 | 2026-09-14 | |
| Eary Infusion of Eptinezumab for TreatmEnt of ACute Post-Traumatic Headaches (ELITE-ACT) Eptinezumab, Placebo - Post Traumatic Headache | Phase 3 | Recruiting | Sunnybrook Health Sciences Centre | 80 | 2026-11-01 | 2026-10-29 |
Showing 20 of 1553. Sign in to see all of them.
Headache (322) · Migraine with Aura (114) · Migraine without Aura (109) · Pain (87) · Headache Disorders (61) · Tension-Type Headache (46) · Epilepsy (41) · Headache Disorders, Primary (28) · Foramen Ovale, Patent (26) · Chronic Pain (24) · Cluster Headache (23) · Depression (22) · Emergencies (22) · Anxiety Disorders (21)
Central Nervous System Diseases (1546) · Nervous System Diseases (1545) · Brain Diseases (1543) · Headache Disorders, Primary (1525) · Headache Disorders (1492) · Pathological Conditions, Signs and Symptoms (492) · Signs and Symptoms (459) · Neurologic Manifestations (444) · Pain (322) · Pathologic Processes (68) · Behavior (62) · Cardiovascular Diseases (60) · Mental Disorders (58) · Immune System Diseases (42)
Sumatriptan (68) · Topiramate (55) · erenumab (50) · rimegepant sulfate (42) · Sodium Chloride (35) · Botulinum Toxins, Type A (32) · Naproxen (31) · eptinezumab (27) · rizatriptan (25) · Metoclopramide (22) · fremanezumab (22) · Saline Solution (21) · galcanezumab (20) · atogepant (19) · Acetaminophen (17)
Danish Headache Center (74) · Pfizer (43) · Eli Lilly and Company (30) · GlaxoSmithKline (28) · Allergan (25) · Amgen (22) · AbbVie (20) · Theranica (20) · IRCCS National Neurological Institute "C. Mondino" Foundation (18) · Merck Sharp & Dohme LLC (18) · Mayo Clinic (16) · H. Lundbeck A/S (15) · Montefiore Medical Center (15) · Thomas Jefferson University (15) · Organon and Co (14)
United States (642) · Denmark (111) · Italy (102) · Turkey (Türkiye) (87) · Spain (80) · Canada (75) · Germany (74) · China (69) · France (61) · United Kingdom (58) · Belgium (42) · Israel (40) · Poland (37) · Japan (33) · Norway (31)
Roger K Cady, MD (9) · Alit Stark Inbar, PhD (7) · Mia Minen, MD (6)
PMID 11914403, PMID 12807523, PMID 8984084, PMID 39982105, PMID 31482569, PMID 32576229, PMID 33781209, PMID 17405970, PMID 31952501, PMID 34823467, PMID 35978286, PMID 37965170, PMID 11284464, PMID 25500317, PMID 30496104, PMID 31291516, PMID 33142014, PMID 34264500, PMID 34874514, PMID 34928306, PMID 35076090, PMID 36125279, PMID 36739511, PMID 37303034, PMID 38462625, PMID 39648629, PMID 41235617, PMID 41652666, PMID 42839212, PMID 11112243, PMID 16135345, PMID 17175134, PMID 17955107, PMID 18662331, PMID 19453963, PMID 19486178, PMID 19546766, PMID 20353434, PMID 20487038, PMID 20548058, PMID 20855373, PMID 21521204, PMID 21883197, PMID 22520687, PMID 22590713, PMID 23731663, PMID 24524844, PMID 24579886, PMID 25080874, PMID 25297013
2019 (14), 2023 (9), 2018 (7), 2015 (6), 2008 (4), 2016 (4), 2014 (3), 2017 (3), 2025 (2), K01NS124911 (2), R01AT011005 (2), 1UG3AT013498-01 (1), 2005 (1), K23AT008406 (1), K23AT009706 (1)